Skip to main content
Premium Trial:

Request an Annual Quote

ProZyme, BiOptic Collaborate on High-Throughput Glycoanalysis System

NEW YORK (GenomeWeb) – ProZyme and BiOptic said on Thursday they are collaborating to develop and commercialize an integrated system for high-throughput glycoanalysis. 

The collaboration will extend ProZyme's portfolio of glycobiology products while leveraging BiOptic's suite of capillary gel electrophoresis instruments, they said. Prozyme will use BiOptic's CGE platforms with fluorescence detection and replaceable gel-cartridge design for the rapid separation and detection of labeled glycans. 

ProZyme's chemistry will be used to prepare enzymatically released and fluorescently labeled glycans on the front end of the Gly-Q system, while customized software and ProZyme N-glycan reference standards will simplify data analysis on the back end. 

ProZyme will exclusively market the system worldwide for N-glycan sample preparation, separation, and analysis. The partners plan to commercialize the Gly-Q system for applications such as biotherapeutic cell line development, they said. 

Financial and other terms of the deal were not disclosed. 

ProZyme is based in Hayward, California and manufactures bioreagents for glycobiology. Taiwan-based BiOptic manufactures CGE instruments for DNA analysis.   

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.